ArticleFrontiers in molecular neuroscience2026
Transcriptional and neurotransmitter signatures associated with regional gray matter alterations in juvenile myoclonic epilepsy.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The neurobiological basis of gray matter (GM) alterations in juvenile myoclonic epilepsy (JME) remains poorly understood. This study aimed to identify robust GM changes and their underlying molecular signatures. Methods: We performed an updated coordinate-based meta-analysis of 15 voxel-based morphometry studies (394 JME patients, 448 healthy controls) and integrated the resulting GM alteration map with data from the Allen Human Brain Atlas and neurotransmitter atlases using advanced spatial correlation, gene enrichment, and network analysis approaches. Results: Our analysis revealed a consistent pattern of GM decreases in the sensorimotor areas and increases in regions implicated in emotion and cognition. These structural changes were spatially correlated with a set of 926 genes enriched for pathways related to ion channel activity, synaptic function, neuronal processes, and cellular metabolism, which showed peak expression during neurodevelopmental periods coinciding with JME onset. Protein-protein interaction analysis identified hub genes from two key functional classes: transcriptional regulators linked to circadian rhythms, and cellular signaling molecules including established monogenic epilepsy genes. Furthermore, the GM map correlated significantly with the spatial distributions of the serotonin, dopamine, and acetylcholine neurotransmitter systems. Discussion: While these associations are based on data from healthy donors and require further validation, our findings bridge the gap between macroscopic brain alterations and their underlying molecular architecture in JME. This provides an integrated model of its pathophysiology and highlights potential therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.